Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech product launch

Abbott Volt PFA System First Canadian Use

Analysis based on 6 articles · First reported Sep 15, 2026 · Last updated Sep 15, 2026

Sentiment
10
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The first Canadian use of Abbott's Volt PFA System reinforces Abbott Laboratories' competitive position in the fast-growing pulsed field ablation market, a positive signal for its electrophysiology franchise revenue. The broader medical device sector may see incremental adoption momentum for PFA technologies, though the immediate financial impact is limited given this is a single first-use milestone rather than a broad commercial rollout.

medical devices healthcare

Abbott Laboratories announced on September 15, 2026 that its Volt Pulsed Field Ablation System was used for the first time in Canada at the McGill University Health Centre in Montreal to treat patients with atrial fibrillation (AFib). The Volt system is a next-generation cardiac ablation technology built on a distinctive balloon-in-basket design that delivers precise, targeted pulsed-field energy with fewer catheter exchanges and reduced radiation exposure than earlier-generation systems. The first Canadian procedure was performed under the leadership of Dr. Atul Verma, director of cardiology at the McGill University Health Centre. Canada — Health Canada authorized the Volt PFA System in April 2026 based on results from the VOLT-AF IDE study, a clinical trial of 392 patients conducted at 40 centres across the United States, Europe, Canada and Australia. The system is also approved and available in the United States, Europe and Australia. Abbott's chief medical officer of electrophysiology, Christopher Piorkowski, highlighted that the system supports conscious sedation as an alternative to general anesthesia, potentially making procedures more efficient and supporting quicker recovery. The Volt system integrates with Abbott's EnSite X EP System for 3D cardiac mapping. AFib affects between 500,000 and nearly one million Canadians and can lead to serious complications including stroke and heart failure if untreated.

70 McGill University Health Centre used Volt PFA System
60 Canada — Health Canada authorized Volt PFA System Abbott Laboratories
stock
Abbott Laboratories is the manufacturer of the Volt PFA System and the central entity of this event. The first Canadian use expands the commercial footprint of its electrophysiology portfolio and supports its competitive position in the PFA market.
Importance 95.0 Sentiment 25.0
priv
McGill University Health Centre is the first Canadian hospital to use the Volt PFA System, positioning it as an early adopter of next-generation ablation technology.
Importance 70.0 Sentiment 10.0
govactor
Canada — Health Canada authorized the Volt PFA System in April 2026, enabling its use in Canada and paving the way for this first procedure.
Importance 50.0 Sentiment 0.0
cnt
Canada is the country where the first use of the Volt PFA System occurred, marking the expansion of the technology into the Canadian healthcare market.
Importance 40.0 Sentiment 5.0
per
Atul Verma, director of cardiology at the McGill University Health Centre, commented on the benefits of the Volt system and its potential to improve procedural consistency and efficiency.
Importance 30.0 Sentiment 0.0
per
Christopher Piorkowski, chief medical officer of Abbott's electrophysiology business, highlighted the conscious sedation option and efficiency benefits of the Volt PFA System.
Importance 25.0 Sentiment 0.0
cnt
The United States is one of the countries where the Volt PFA System is already approved and available, and where part of the VOLT-AF IDE trial was conducted.
Importance 20.0 Sentiment 0.0
cnt
Australia is one of the countries where the Volt PFA System is approved and available, and where part of the VOLT-AF IDE trial was conducted.
Importance 15.0 Sentiment 0.0
loc
Europe is one of the regions where the Volt PFA System is approved and available, and where part of the VOLT-AF IDE trial was conducted.
Importance 15.0 Sentiment 0.0
Canada trade rivals ↔ United States Canada views the United States as a strained partner and trade rival, facing significant tariffs and renegotiation of tr
Canada related ↔ Australia
United States related ↔ Australia
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.